ViaDerma Inc (VDRM)

[ORCA]

LET US PAY ATTENTION TO THIS PR.WHY THE 500K DID NOT SHOW ON Q3 REPORT??
THE TIMING WAS VERY CLOSE.MAYBE IT WAS NOT RECEIVED ON TIME BEFORE THE END OF Q3.JUST BECAUSE YOU SHIPPED THE ORDER IT DOES NOT MEAN IT WAS RECEIVED BY THE OTHER PARTY ON TIME.THEY HAVE TO GO THROUGH A LOT OF PAPER WORK.CUSTOMS EXAMINATION.ETC.
OR THE PRODUCT WAS RECEIVED ON TIME BUT IT WAS NOT PAID ON TIME TO PUT IT ON THE BOOKS IN Q3.
A LOT OF COMPANIES RUN THROUGH THIS KIND OF PROBLEMS.YOU CAN NOT RECORD REVENUES IF YOU ARE NOT PAID.LOL.SO THIS IS MY TAKE.I WAS IN A STOCK AMMX.THEY HAD SIMILAR PROBLEMS.
WE WERE EXPECTING A TON OF REVENUES.AND THEN THECOMPANY WAS SAYING THAT THEY COULD NOT RECORD THE REVENUES,FOR THE SPECIFIC Q BECAUSE IT WAS NOT PAID YET.SO WE SAW IT ON THE NEXT Q.
TRUST ME THIS HAPPENS ALL THE TIME WITH COMPANIES.
ViaDerma Completes First Shipment of 500,000 Units to Nigeria
Press Release | 09/10/2024
LOS ANGELES, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC: VDRM), a specialty pharmaceutical company known for developing innovative transdermal drug delivery systems, is pleased to announce the successful completion of its first shipment of 500,000 units of its flagship product, a tetracycline based topical antibiotic to Nigeria. The shipment was sent out as planned before the end of August 2024.

This milestone marks a significant step forward in ViaDerma’s international expansion strategy, as the company continues to meet the growing global demand for its products. The timely execution of this shipment demonstrates ViaDerma’s commitment to delivering high-quality pharmaceutical solutions to key markets around the world.

A second shipment of an additional 500,000 units is already in preparation and is expected to be dispatched before the end of October 2024. This next phase of shipments highlights ViaDerma’s dedication to ensuring a consistent supply to its partners in Nigeria, aligning with the company’s broader vision of expanding into emerging markets.

Additionally, ViaDerma is pleased to announce that CEO Dr. Christopher Otiko has successfully returned from his recent follow-up trip to Dubai, where he engaged with key partners in the region. The trip was highly productive, with strong continued interest from local partners, further solidifying the Company’s plans to strengthen alliances and expand distribution across the Middle East.

“We are thrilled to have successfully completed our first large-scale shipment to Nigeria, furthering our mission to make wound care more accessible globally,” said Dr. Christopher Otiko, CEO of ViaDerma. “We look forward to building on this momentum with our upcoming shipment in October as we continue to expand our presence across Africa, the Middle East and other regions.”

ViaDerma’s innovative products, including its patented transdermal delivery systems, have been well-received in international markets, helping address the growing need for effective wound care solutions. The company remains committed to increasing access to life-saving medications and wound care products in underserved regions.